

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 10<sup>th</sup> November, 2016

**ORDER**

S.O. 3433(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**Table**

<b>Sl. No.</b>	<b>Name of the Scheduled Formulation / Brand Name</b>	<b>Strength</b>	<b>Unit</b>	<b>Manufacturer &amp; Marketing Company respectively</b>	<b>Retail Price (Rs.)</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>(5)</b>	<b>(6)</b>
1.	Teneligliptin + Metformin HCl Tablet  (Tenlimac M 1000)	Each uncoated bilayer tablet contains:  Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg  Metformin HCl 1000mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	11.65
2.	Teneligliptin + Metformin HCl Tablet	Each uncoated bilayer tablet contains:  Teneligliptin Hydrobromide	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.	11.65

	(Tenzulix M 1000)	Hydrate eq. to Teneligliptin 20mg  Metformin HCl 1000mg (as extended release)			
3.	Teneligliptin + Metformin HCl Tablet  (Tenglyn M 1000)	Each uncoated bilayered tablet contains:  Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg  Metformin HCl 1000mg (as sustained release form)	1 Tablet	M/s Cadila Healthcare Ltd.	11.65
4.	Teneligliptin + Metformin HCl (SR)Tablet	Each uncoated bilayer tablet contains:  Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg  Metformin HCl 1000mg (as sustained release form)	1 Tablet	M/s Lupin Limited	11.65
5.	Teneligliptin + Metformin HCl Tablet  (Tenzulix M 500)	Each uncoated bilayer tablet contains:  Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg  Metformin HCl 500mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.	11.14

6.	Teneligliptin + Metformin HCl Tablet  (Tenlimac M 500)	Each uncoated bilayer tablet contains:  Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg  Metformin HCl 500mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	11.14
7.	Teneligliptin + Metformin HCl (ER)Tablet	Each uncoated bilayer tablet contains:  Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg  Metformin HCl 500mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Anthem BioPharma Pvt. Ltd.	11.14
8.	Diclofenac Sodium + Paracetamol Tablet	Each uncoated tablet contains:  Diclofenac Sodium 50mg  (Gastro-Resistant Pellets)  Paracetamol 325mg	1 Tablet	M/s Windlas Biotech Ltd.	2.30
9.	r- HuErythropoietin Injection  (Zyrop 40000)	Each Lyophilized vial contains:  r-HuErythropoietin (r-HuEPO) 40000 IU	Each Pack	M/s Cadila Healthcare Ltd.	8938.96
10.	r- HuErythropoietin Injection  (Zyrop 20000)	Each Lyophilized vial contains:  r-HuErythropoietin (r-HuEPO) 20000 IU	Each Pack	M/s Cadila Healthcare Ltd.	4925.59

11.	Voglibose + Metformin HCl (SR) tablet	Each uncoated bilayered tablet contains:  Metformin HCl (in sustained release form) – 500mg  Voglibose 0.3mg	10 Tablets	M/s Synokem Pharmaceuticals Ltd. / M/s Ajanta Pharma Ltd.	57.62
-----	---------------------------------------	--	------------	---	-------

Note:

(a) The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.

(d) The above mentioned retail price is applicable only to the individual manufacturers / marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

(e) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.

PN/170/38/2016/F

F. No. 8(38)/2016/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director